JP4024366B2 - ポリペプチド - Google Patents

ポリペプチド Download PDF

Info

Publication number
JP4024366B2
JP4024366B2 JP32971597A JP32971597A JP4024366B2 JP 4024366 B2 JP4024366 B2 JP 4024366B2 JP 32971597 A JP32971597 A JP 32971597A JP 32971597 A JP32971597 A JP 32971597A JP 4024366 B2 JP4024366 B2 JP 4024366B2
Authority
JP
Japan
Prior art keywords
polypeptide
cells
seq
amino acid
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP32971597A
Other languages
English (en)
Japanese (ja)
Other versions
JPH10262686A (ja
JPH10262686A5 (enExample
Inventor
康三 山本
岩夫 岡本
雅司 栗本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hayashibara Seibutsu Kagaku Kenkyujo KK
Original Assignee
Hayashibara Seibutsu Kagaku Kenkyujo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hayashibara Seibutsu Kagaku Kenkyujo KK filed Critical Hayashibara Seibutsu Kagaku Kenkyujo KK
Priority to JP32971597A priority Critical patent/JP4024366B2/ja
Priority to TW086117857A priority patent/TW565569B/zh
Priority to EP97309632A priority patent/EP0845530A3/en
Priority to KR1019970064563A priority patent/KR100496460B1/ko
Priority to US08/982,285 priority patent/US6476197B1/en
Publication of JPH10262686A publication Critical patent/JPH10262686A/ja
Priority to US10/260,576 priority patent/US7037685B2/en
Publication of JPH10262686A5 publication Critical patent/JPH10262686A5/ja
Application granted granted Critical
Publication of JP4024366B2 publication Critical patent/JP4024366B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP32971597A 1996-11-29 1997-11-14 ポリペプチド Expired - Fee Related JP4024366B2 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP32971597A JP4024366B2 (ja) 1996-11-29 1997-11-14 ポリペプチド
TW086117857A TW565569B (en) 1996-11-29 1997-11-27 Novel polypeptides for inducing the production of interferon-gamma
EP97309632A EP0845530A3 (en) 1996-11-29 1997-11-28 Interferon gamma inducing factor
KR1019970064563A KR100496460B1 (ko) 1996-11-29 1997-11-29 폴리펩티드
US08/982,285 US6476197B1 (en) 1996-11-29 1997-12-01 Polypeptides having interferon-γ inducing activity
US10/260,576 US7037685B2 (en) 1996-11-29 2002-10-01 DNA encoding loypeptides having interferon-γ inducing activity

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP33303796 1996-11-29
JP9-20906 1997-01-21
JP8-333037 1997-01-21
JP2090697 1997-01-21
JP32971597A JP4024366B2 (ja) 1996-11-29 1997-11-14 ポリペプチド

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007006295A Division JP2007143555A (ja) 1996-11-29 2007-01-15 ポリペプチド

Publications (3)

Publication Number Publication Date
JPH10262686A JPH10262686A (ja) 1998-10-06
JPH10262686A5 JPH10262686A5 (enExample) 2004-11-18
JP4024366B2 true JP4024366B2 (ja) 2007-12-19

Family

ID=27283214

Family Applications (1)

Application Number Title Priority Date Filing Date
JP32971597A Expired - Fee Related JP4024366B2 (ja) 1996-11-29 1997-11-14 ポリペプチド

Country Status (5)

Country Link
US (2) US6476197B1 (enExample)
EP (1) EP0845530A3 (enExample)
JP (1) JP4024366B2 (enExample)
KR (1) KR100496460B1 (enExample)
TW (1) TW565569B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023013763A1 (ja) 2021-08-06 2023-02-09 国立大学法人 長崎大学 がんの治療剤
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69519454T2 (de) * 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
JP3955352B2 (ja) 1997-02-25 2007-08-08 株式会社林原生物化学研究所 破骨細胞形成阻害剤
TWI227136B (en) 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
AU761520B2 (en) * 1998-09-15 2003-06-05 Genetics Institute, Llc Treatment of Kaposi's Sarcoma with IL-12
US6432678B1 (en) 1999-06-21 2002-08-13 Smithkline Beecham Corporation Macaca cynomolgus IL 18
CA2399148A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
DE60208692T2 (de) * 2001-03-08 2006-07-13 Ares Trading S.A. Interleukin -18 mutantenproteine, deren herstellung und verwendung
BR0206112A (pt) * 2001-10-10 2005-05-10 Centocor Inc Vacinas de ácido nucléico usando ácidos nucléicos de codificação de antìgeno de tumor com ácido nucleìco de codificação de auxiliar de citocina
KR100468482B1 (ko) * 2002-04-11 2005-01-27 양문식 효모 발현 시스템을 이용한 인터루킨-18 단백질의생산방법
US20050079153A1 (en) * 2002-08-14 2005-04-14 Pfizer Inc. Methods for enhancing immune functions in neonatal mammals by administration of IL-18
EP1613274B1 (en) * 2003-04-15 2010-03-03 GlaxoSmithKline LLC Human il-18 substitution mutants and their conjugates
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
WO2005075648A1 (en) * 2004-01-28 2005-08-18 Gifu University Interleukin-18 mutant proteins
AU2005277404A1 (en) * 2004-08-20 2006-03-02 Smithkline Beecham Corporation Methods of healing wounds by administering human IL-18
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
EP3247833A4 (en) * 2015-01-14 2018-09-19 Gregory Van Buskirk Improved fabric treatment method for stain release
WO2019051015A1 (en) 2017-09-06 2019-03-14 Yale University VARIANTS OF INTERLEUKIN-18 AND METHODS OF USE
US12029778B2 (en) 2019-05-13 2024-07-09 Yale University Interleukin-18 mimics and methods of use
EP4293039A4 (en) 2021-02-10 2025-07-16 Univ Nagasaki NEW VARIANT OF HUMAN INTERLEUKIN-18 AND ITS USE
AU2022414067A1 (en) * 2021-12-15 2024-05-23 Genentech, Inc. Stabilized il-18 polypeptides and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518546A (en) * 1982-06-18 1985-05-21 General Electric Company Preparation of yttria-gadolinia ceramic scintillators by sintering and gas hot isostatic pressing
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
JP3122963B2 (ja) 1995-02-10 2001-01-09 株式会社林原生物化学研究所 モノクローナル抗体
DE69519454T2 (de) * 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
JP2952750B2 (ja) 1995-02-23 1999-09-27 株式会社林原生物化学研究所 モノクローナル抗体
TW464656B (en) * 1994-11-15 2001-11-21 Hayashibara Biochem Lab Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease
JP2724987B2 (ja) * 1994-11-15 1998-03-09 株式会社林原生物化学研究所 インターフェロン−γの産生を誘導するポリペプチド
JPH08207189A (ja) 1995-02-03 1996-08-13 Toppan Printing Co Ltd 内装用化粧シートおよびその製造方法
US5776731A (en) * 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
AU3116697A (en) * 1996-05-20 1997-12-09 Schering Corporation Human interleukin-1j and antagonists thereof
FR2882746B1 (fr) 2005-03-01 2007-04-27 Commissariat Energie Atomique Procede de preparation d'une solution sol-gel et utilisation de cette solution pour constituer un revetement pour proteger un substrat a surface metallique
US7865223B1 (en) 2005-03-14 2011-01-04 Peter Bernreuter In vivo blood spectrometry
WO2007067178A1 (en) 2005-12-09 2007-06-14 The Gates Corporation Auxiliary power system for a motor vehicle
US7645909B2 (en) 2006-08-10 2010-01-12 Cognis Ip Management Gmbh Linear and branched alcohol ethoxylates for controlling insects
DE102006038439A1 (de) 2006-08-16 2008-02-21 Dürr GmbH & Co. KG Luft- und Prozessortechnik Anlage zur Erzeugung eines an einer vorgegebenen Komponente angereicherten Nutzgases

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023013763A1 (ja) 2021-08-06 2023-02-09 国立大学法人 長崎大学 がんの治療剤
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
US12286463B1 (en) 2023-12-29 2025-04-29 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same

Also Published As

Publication number Publication date
EP0845530A3 (en) 2000-01-19
TW565569B (en) 2003-12-11
KR100496460B1 (ko) 2005-11-16
EP0845530A2 (en) 1998-06-03
US6476197B1 (en) 2002-11-05
JPH10262686A (ja) 1998-10-06
US20030092130A1 (en) 2003-05-15
US7037685B2 (en) 2006-05-02
KR19980042925A (ko) 1998-08-17

Similar Documents

Publication Publication Date Title
JP4024366B2 (ja) ポリペプチド
US7875709B2 (en) Nucleic acids encoding interleukin-18 mutants
KR100607609B1 (ko) Ｉｌ-2 선택성 작용제 및 길항제
RU2711979C2 (ru) Белковый комплекс интерлейкина 15 и его применение
CN112724259B (zh) 人血清白蛋白与白介素2的融合蛋白及其用途
CN105705641B (zh) 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子
Vandevoorde et al. Induced expression of trimerized intracellular domains of the human tumor necrosis factor (TNF) p55 receptor elicits TNF effects
AU2002324249A1 (en) Interleukin-18 mutants, their production and use
JPH09289896A (ja) 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
US6207641B1 (en) Pharmaceutical composition containing IFN-γ inducing polypeptide or factor for treating and/or preventing IFN-γ susceptive diseases
FI117054B (fi) Interleukiini-15:n valmistusmenetelmä ja sitä koodaava DNA-sekvenssi
JP2007143555A (ja) ポリペプチド
JP4026923B2 (ja) ポリペプチド
JP2589094B2 (ja) 抗悪性腫瘍剤
JP3993652B2 (ja) 感受性疾患剤
JP3689111B2 (ja) インターロイキン１５
AU733126B2 (en) Polypeptides
JPH04103599A (ja) 融合ポリペプチド
JPH03505730A (ja) ヒトにヒト好中球走化因子を投与することによる免疫不全状態に起因する疾患の治療法
HK1084151B (en) Interleukin-18 mutants, their production and use

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060221

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061114

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070925

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20071003

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101012

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111012

Year of fee payment: 4

LAPS Cancellation because of no payment of annual fees